SCHEMBL7143214

SCHEMBL7143214

COc1ccc2c(c1)N(C)C(=C1SC(=Nc3cccc(C(C(N)=O)N(C)C)c3)N(Cc3ccco3)C1=O)S2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.58
MEN1 O00255 8/20 0.58
MAPT P10636 7/20 0.58
ALDH1A1 P00352 7/20 0.58
LMNA P02545 6/20 0.58
TP53 P04637 2/20 0.58
TSHR P16473 1/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
ESR2 Q92731 1/20 0.58
HSD17B10 Q99714 1/20 0.58
NPSR1 Q6W5P4 4/20 0.56
RXFP1 Q9HBX9 2/20 0.56
KDM4E B2RXH2 2/20 0.41
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 2/20 0.36
GAA P10253 2/20 0.36
FAAH O00519 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2332416 0.83 MAPT (0.58) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2332419 0.83 MAPT (0.58) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL12449319 0.74 KMT2A (0.48) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2337281 0.74 KMT2A (0.48) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2337286 0.74 KMT2A (0.48) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2335347 0.68 KMT2A (0.43) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2335343 0.68 KMT2A (0.43) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2337613 0.68 KMT2A (0.41) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2336683 0.68 KMT2A (0.41) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2338552 0.68 KMT2A (0.44) KMT2AMEN1MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212111-A1 Heterocyclic modulators of nuclear receptors AKARNA THERAPEUTICS, LTD. (GB) 2003-11-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212111-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 KMT2A 2838/4885MEN1 4537/4885MAPT 4111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.